Human Papilloma Virus/HPV Test and Pap Smear/Test Market worth $3.94 billion by 2030
The report "Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030", is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0% during the forecast period.
Browse 311 market data Tables and 53 Figures spread through 257 Pages and in-depth TOC on "Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/hpv-testing-pap-test-market-214207371.html
The growing prevalence of human papillomavirus (HPV) infections and the associated rise in cervical cancer cases are major drivers of the HPV testing and Pap test market. HPV is the most common sexually transmitted infection worldwide, and persistent infection with high-risk HPV strains is the leading cause of cervical cancer. According to global health authorities, cervical cancer remains one of the top cancers affecting women, particularly in low- and middle-income countries where screening coverage is limited. This rising disease burden has heightened the need for effective and widespread screening programs, creating sustained demand for both HPV molecular assays and Pap cytology tests. Governments, healthcare providers, and non-profit organizations are increasingly prioritizing early detection through organized screening initiatives to reduce morbidity and mortality. The urgency to diagnose precancerous lesions and intervene at an early stage is driving the continuous adoption of advanced diagnostic technologies.
By test type, the HPV testing segment accounted for the largest share of the HPV testing and Pap test market in 2024.
Based on test type, the HPV testing and Pap test market is segmented into HPV testing and Pap tests. In 2024, HPV testing accounted for the dominant share of the market. This dominance is attributed to the growing global shift toward HPV testing as the primary screening method for cervical cancer, supported by its higher sensitivity and accuracy compared to Pap cytology alone. Regulatory bodies and health organizations, including the WHO, are increasingly recommending HPV-based screening protocols, which have accelerated adoption across both developed and emerging regions. The ability of HPV tests to detect high-risk viral strains before the development of precancerous lesions provides significant clinical value, driving their preference over traditional Pap tests. Additionally, advancements in molecular diagnostics, automation, and high-throughput platforms have further strengthened the position of HPV testing. While Pap tests continue to play an important role in many screening programs, the rising emphasis on early detection and prevention through molecular assays is ensuring HPV testing remains the dominant test type in the global market.
By care setting, the hospitals segment is projected to be the fastest-growing segment during the forecast period.
Based on care setting, the HPV testing and Pap test market is segmented into hospitals, diagnostic laboratories, and physicians’ offices & clinics. Hospitals held the largest share of the market in 2024 and are also projected to register the fastest growth over the forecast period. This growth is driven by their ability to handle large-scale cervical cancer screening programs, supported by advanced infrastructure, trained specialists, and integrated diagnostic facilities. Hospitals are increasingly adopting molecular HPV testing platforms and automation technologies, which allow for high-throughput testing and enhanced accuracy. In addition, they serve as referral centers for complex cases and play a central role in organized national and regional screening initiatives, which continue to boost testing volumes. The increasing emphasis on preventive healthcare, coupled with hospital investments in digital pathology and data integration systems, is expected to further strengthen their role. These factors position hospitals as not only the dominant care setting but also the fastest-expanding segment in the global HPV testing and Pap test market.
North America represents the largest regional HPV testing and Pap test market.
The HPV testing and Pap test market has been segmented into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the leading position in the HPV testing and Pap test market, supported by a strong healthcare infrastructure, established diagnostic networks, and strict regulatory standards that emphasize accuracy and reliability in testing. The region conducts a high volume of cervical cancer screenings each year, driven by growing awareness, preventive healthcare programs, and adoption of early detection initiatives. This fuels steady demand for consumables, reagents, and testing platforms that provide consistent results. Market growth is further supported by the presence of major global players in HPV and Pap testing, many of which are based in or have significant operations in North America. These companies invest in advanced molecular assays, automated testing systems, and digital tools that enhance efficiency and minimize errors. High healthcare spending, continuous R&D investment, and the rapid adoption of new diagnostic technologies collectively sustain North America’s leadership in the global HPV testing and Pap test market.
The major players operating in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, In. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd. (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
